Keyword: Boehringer Ingelheim

After testing local market TV last year, Boston Scientific has expanded its TV media run for its Watchman heart implant device.

It’s that time of year again—the time when lead PBM Express Scripts ignites pharma’s ire with a brand-new list of formulary exclusions.

Biogen and Eisai's anti-amyloid candidate shows promise; Otsuka signs two M&A deals; Samsung BioLogics faces criminal probe over Biogen JV agreement.

Boehringer Ingelheim is expanding the $77 million contract biologics plant it opened last year in Shanghai.

In a new post-hoc analysis of Jardiance's CV outcomes test, investigators found that the drug reduced kidney disease progression.

Invokana carries a warning for amputation risks, but an analysis found the drug lowered heart failure hospitalizations without increasing those risks.

Pharma advertisers scored big at Cannes Lions Health with double-digit wins and renewed momentum for next year.

Though the top prize eluded the field, 10 pharma companies racked up gold, silver or bronze Lions for their marketing and advertising efforts.

In a phase 3 study, Novo said oral semaglutide helped diabetes patients manage their blood sugar levels better than Jardiance. 

Portola has won FDA approval of Andexxa, its antidote for some next-gen bloodthinners, but a manufacturing upgrade will limit initial supplies.